{"id":22094,"date":"2024-09-23T12:35:00","date_gmt":"2024-09-23T12:35:00","guid":{"rendered":"https:\/\/clinlabint.com\/?p=22094"},"modified":"2024-09-23T12:35:00","modified_gmt":"2024-09-23T12:35:00","slug":"newcells-biotech-enhances-pre-clinical-drug-development-with-advanced-imaging-suite","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/newcells-biotech-enhances-pre-clinical-drug-development-with-advanced-imaging-suite\/","title":{"rendered":"Newcells Biotech enhances pre-clinical drug development with advanced imaging suite"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Newcells Biotech enhances pre-clinical drug development with advanced imaging suite<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Newcastle-based Newcells Biotech has unveiled a state-of-the-art imaging suite, strengthening its capabilities in pre-clinical drug development. The company, known for its in vitro models and bespoke assay services, aims to improve the prediction of in vivo human outcomes with this latest investment.<\/strong><\/p>\n

<\/p>\n

Advanced technology for deeper insights<\/h4>\n

The new suite features high-content and high-throughput imaging equipment, including an ImageXpress\u00ae Confocal HT.ai High-Content Imaging System, a ZEISS Axio Observer system with Apotome 3, and an ImageXpress Pico Automated Cell Imaging System. These technologies enable more comprehensive data generation and analysis across Newcells\u2019 in vitro retina, kidney, and lung models.<\/p>\n

Enhanced lung fibrosis assay<\/h4>\n

Alongside the imaging suite, Newcells has launched an advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. This high-throughput, high-sensitivity assay allows for customisable and rapid assessment of anti-fibrotic drug candidates. The improved version offers higher-resolution data with simultaneous assessment of four separate data outputs, potentially enhancing the predictivity of drug effects on pulmonary fibrosis.<\/p>\n

Dr Mike Nicholds, CEO and Co-Founder of Newcells Biotech, highlighted the significance of this development: \u201cThe launch of our new imaging suite and enhanced fibrotic disease screening assay is a key step in our strategy to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs.\u201d<\/p>\n

Future applications in drug development<\/h4>\n

Nicholds also noted the potential for further applications: \u201cAs the capabilities of analytical technology in imaging and omics accelerates, we can see opportunities to further add value to our customers by applying these techniques to provide mechanistic data on how innovative new therapies will affect human tissues and organs.\u201d For more information on Newcells Biotech\u2019s imaging assays and services, visit:
\nwww.newcellsbiotech.co.uk\/imaging<\/a><\/p>\n

Digital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n